Please try another search
For the three months ended 31 December 2020, InMedPharmaceuticals Inc revenues was not reported. Net lossdecreased 10% to $2.2M. Lower net loss reflects OperatingExpenses Research and developm decrease of 42% to $938K(expense), Unrealized gain on derivative warrants lincrease from $0K to $243K (income). Basic Earnings perShare excluding Extraordinary Items increased from -$0.48to -$0.37.
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -1.93 | -1.68 | -1.77 | -2.44 |
Net Income | -2.24 | -1.71 | -1.85 | -2.25 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Assets | 11.75 | 6.75 | 7.8 | 9.58 |
Total Liabilities | 4.16 | 2.25 | 1.92 | 1.86 |
Total Equity | 7.59 | 4.49 | 5.88 | 7.72 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -3.17 | -1.45 | -7.82 | -6.3 |
Cash From Investing Activities | 0 | 0 | 3.96 | 3.96 |
Cash From Financing Activities | 6.89 | -0.09 | -0.11 | -0.05 |
Net Change in Cash | 4.22 | -1.53 | -3.97 | -2.39 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review